Evidence map›Paper›PMID 42712743›Full record

ArticleFrontiers in medicine2026

Case Report: Acquired CDKN2A/B deletion and mTOR inhibitor resistance in TSC2-mutant metastatic epithelioid angiomyolipoma.

Shuai He, Jing Yang, Jiguang Yang, Chunxia Li, Juan Shen, Xiaolong Ye, Zuping Liu, Wenhao Shen, Jun Zheng, Yongquan Wang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuai He *Department of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Jing Yang *International Center for Aging and Cancer, Hainan Medical University, Haikou, Hainan, China.
Jiguang Yang *Department of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Chunxia LiDepartment of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Juan ShenDepartment of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Xiaolong YeDepartment of Pathology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Zuping LiuDepartment of Pathology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Wenhao ShenDepartment of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Jun ZhengDepartment of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Yongquan WangDepartment of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired resistance to mTOR inhibition remains a major challenge in TSC2-mutant metastatic epithelioid angiomyolipoma (EAML). We report a 30-year-old woman with metastatic EAML harboring biallelic TSC2 mutations who achieved a complete response to everolimus but developed disease progression after 16 months. Tumor rebiopsy revealed persistent TSC2 mutations and acquired CDKN2A/B deletion, accompanied by increased Ki-67 and emergence of TFE-3 immunoreactivity and focal S-100 positivity. These findings suggest a potential association between CDKN2A/B loss and aggressive tumor behavior after mTOR inhibition, although causality remains unproven. CDK4/6-targeted strategies may warrant further investigation in this context.

Indexed as

acquired resistancecase reportCDKN2A/Bepithelioid angiomyolipomaeverolimusmetastatic renal tumorTSC2 mutation

Identifiers

PMID42712743
PMCPMC13550966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.